Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2011 to 2025 of 9004 results

  1. TUC Safety Valve to prevent balloon inflation in the urethra during transurethral catheterisation (MT512)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  2. Zavegepant for treating acute migraine [TSID11998]

    Awaiting development Reference number: GID-TA11527 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Troriluzole for spinocerebellar ataxia [ID6456]

    Awaiting development Reference number: GID-TA11549 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  7. Ceftobiprole medocaril for treating community- or hospital-acquired pneumonia in people 3 months to 17 years [TSID11819]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  8. Subcutaneous ocrelizumab for treating primary progressive or relapsing multiple sclerosis [TSID11895]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  9. Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. Remimazolam for general anaesthesia [ID3796]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  11. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  12. Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]

    In development Reference number: GID-TA10990 Expected publication date: TBC

    Technology appraisal guidance
    In development

  13. Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]

    Awaiting development Reference number: GID-TA10748 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]

    Awaiting development Reference number: GID-TA10638 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development